Literature DB >> 2802548

Cefotiam disposition in markedly obese athlete patients, Japanese sumo wrestlers.

K Chiba1, M Tsuchiya, J Kato, K Ochi, Z Kawa, T Ishizaki.   

Abstract

Markedly obese athletes like Japanese sumo wrestlers may frequently suffer various traumas which result in the prophylaxis or treatment of posttraumatic infection with antibiotics. However, appropriate dosage regimens in this group of patients have not been fully known for many antibiotics. Therefore, we studied the kinetic disposition of cefotiam, a parenteral, broad-spectrum cephalosporin with activity against gram-positive and -negative bacteria, after an intravenous dose (2 g) infused over 30 min into 15 sumo wrestler patients with an excess body weight (130 to 220% of ideal body weight) and 10 control patients with a normal weight (90 to 102% of ideal body weight). Mean (+/- standard deviation) clearance and steady-state volume of distribution were significantly greater in the sumo wrestler than in the control group (38.3 +/- 9.4 versus 23.5 +/- 6.0 liters/h, P less than 0.001, and 30.2 +/- 8.0 versus 17.9 +/- 6.1 liters, P less than 0.001). Mean elimination half-life was slightly but significantly longer in the sumo wrestler than in the control group (0.91 +/- 0.14 versus 0.74 +/- 0.20 h, P less than 0.05). However, mean residence time did not differ between the two groups (0.79 +/- 0.10 versus 0.75 +/- 0.14 h). The statistical differences in clearance and volume of distribution between the two groups disappeared when these kinetic parameters were corrected for body surface area, but not for total body weight or ideal body weight. The results suggest that the dosage calculation of cefotiam, a hydrophilic antibiotic, should be made on the basis of body surface area in morbidly obese athlete or sumo wrestler patients. However, whether this recommendation should extend to other nonathlete obese subjects remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2802548      PMCID: PMC172622          DOI: 10.1128/AAC.33.8.1188

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Pharmacokinetics of cefotiam in humans.

Authors:  M C Rouan; J B Lecaillon; J Guibert; J Modai; J P Schoeller
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

2.  A pharmacokinetic analysis program (multi) for microcomputer.

Authors:  K Yamaoka; Y Tanigawara; T Nakagawa; T Uno
Journal:  J Pharmacobiodyn       Date:  1981-11

Review 3.  Drug disposition in obese humans. An update.

Authors:  D R Abernethy; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

4.  Pharmacokinetics and dosage adjustment of cefotiam in renal impaired patients.

Authors:  M C Rouan; U Binswanger; F Bammatter; W Theobald; J P Schoeller; J Guibert
Journal:  J Antimicrob Chemother       Date:  1984-06       Impact factor: 5.790

5.  Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients.

Authors:  L A Bauer; W A Edwards; E P Dellinger; D A Simonowitz
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Pharmacokinetics of cefotiam administered intravenously and intramuscularly to healthy adults.

Authors:  A M Brisson; A Bryskier; L Millerioux; J B Fourtillan
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

7.  Definition, measurement, and classification of the syndromes of obesity.

Authors:  G A Bray
Journal:  Int J Obes       Date:  1978

Review 8.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 9.  Pharmacokinetics of drugs in obesity.

Authors:  D R Abernethy; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

10.  Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects.

Authors:  R L Yost; H Derendorf
Journal:  Ther Drug Monit       Date:  1986       Impact factor: 3.681

View more
  6 in total

1.  Cefepime dosing in the morbidly obese patient population.

Authors:  Barrie S Rich; Rebecca Keel; Vanessa P Ho; Harma Turbendian; Cheguevara I Afaneh; Gregory F Dakin; Alfons Pomp; David P Nicolau; Philip S Barie
Journal:  Obes Surg       Date:  2012-03       Impact factor: 4.129

2.  Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults.

Authors:  M Chen; A N Nafziger; G L Drusano; L Ma; J S Bertino
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

Review 3.  Preventing surgical site infections after bariatric surgery: value of perioperative antibiotic regimens.

Authors:  Teena Chopra; Jing J Zhao; George Alangaden; Michael H Wood; Keith S Kaye
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2010-06       Impact factor: 2.217

Review 4.  Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics.

Authors:  D T Bearden; K A Rodvold
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

5.  Obesity Is Not Associated with Antimicrobial Treatment Failure for Intra-Abdominal Infection.

Authors:  Zachary C Dietch; Therese M Duane; Charles H Cook; Patrick J O'Neill; Reza Askari; Lena M Napolitano; Nicholas Namias; Christopher M Watson; Daniel L Dent; Brandy L Edwards; Puja M Shah; Christopher A Guidry; Stephen W Davies; Rhett N Willis; Robert G Sawyer
Journal:  Surg Infect (Larchmt)       Date:  2016-03-30       Impact factor: 2.150

6.  Fractal Geometry-Based Decrease in Trimethoprim-Sulfamethoxazole Concentrations in Overweight and Obese People.

Authors:  R G Hall; J G Pasipanodya; C Meek; R D Leff; M Swancutt; T Gumbo
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-11-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.